Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRO-PSC-001
- Development stage
- Preclinical
- Lead developer
- Prodigy Biotech
- Modality
- Antibody-Based Therapeutics
01
Overview
PRO-PSC-001 is an investigational IgY (immunoglobulin Y) antibody therapeutic being developed by Prodigy Biotech for the treatment of Primary Sclerosing Cholangitis (PSC). As part of Prodigy's core technology platform, PRO-PSC-001 is designed to selectively target and neutralize specific microbial components or toxins in the gastrointestinal tract that contribute to the pathogenesis of PSC. This approach aims to modulate the gut-liver axis to reduce biliary inflammation and fibrosis. The candidate is currently in the preclinical stage of development.
Beyond the preview
Go deeper on PRO-PSC-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRO-PSC-001.